Two clinical trials have been completed with<unk> . The EVOLVE study and the MOA study. , there are two active phase 1 trials: OCTAVE (in ovarian cancer) and SPICE (in multiple solid tumor indications) Of the T-SIGn viruses, NG-350A has an ongoing clinical study.
Enadenotucirev
Brexucabtagene autoleucel
Seviteronel
Voretigene neparvovec
Belantamab mafodotin
Crofelemer
Ciltacabtagene autoleucel
Idecabtagene vicleucel